Kos Niaspan/Simvastatin Combination NDA Planned For 2006
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Kos is targeting an NDA for its Niaspan/simvastatin combination product for 2006, following the completion of two pivotal trials in patients with mixed dyslipidemia.